Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 ZL-1310 vs investigator's choice in relapsed small cell lung cancer
jRCT2031250762Phase 3Recruiting
- Sponsor
- Zai Lab
- Start
- May 2026
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 3, randomised, open-label trial of zocilurtatug pelitecan in small cell lung cancer (SCLC) (2 arms), sponsored by Zai Lab. Primary endpoints: Confirmed objective response rate (ORR) by BICR per RECIST v1.1 and Overall survival (OS). Started May 2026; status: recruiting.
02
Drugs
zocilurtatug pelitecan
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on jRCT2031250762.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031250762.